{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-041752","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.769945+00:00","generated_at":"2026-06-27T08:22:30.409057+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytomX CFO Carlos Campoy takes temporary leave; VP Chris Ogden to act as interim principal accounting officer","bullets":["CFO Carlos Campoy begins temporary personal leave effective Feb 14, 2022, but remains CFO and principal financial officer.","Chris Ogden, VP Finance and Accounting, designated as interim principal accounting officer.","Ogden's annual base salary set at $315,270 with discretionary bonus target of 30% of salary.","Ogden has severance agreement providing up to 9 months base salary plus benefits and prorated bonus.","Ogden joined CytomX in Aug 2021 after 15 years at Eli Lilly, most recently as CFO of Lilly's diabetes division."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-041752","json":"https://secwatch.observer/filing/0001193125-22-041752.json","markdown":"https://secwatch.observer/filing/0001193125-22-041752.md","text":"https://secwatch.observer/filing/0001193125-22-041752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522041752/0001193125-22-041752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522041752/d495623d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:22:30.409057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3010d38a70","claim":"Chris Ogden was appointed as interim principal accounting officer at CytomX Therapeutics, Inc..","evidence_excerpt":"In connection with Mr. Campoy’s personal leave of absence, the Company’s Board of Directors designated Chris Ogden, the Company’s Vice President, Finance and Accounting, to assume the responsibilities of interim principal accounting officer, effective February 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522041752/0001193125-22-041752-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"interim principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}